Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Theravance Biopharma, Inc. - Ordinary Shares (NQ:TBPH)

19.83 UNCHANGED
Streaming Delayed Price Updated: 3:21 PM EST, Feb 3, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Theravance Biopharma, Inc. - Ordinary Shares

< Previous 1 2 3 4 5 6 Next >
Stay updated with the stocks that are on the move in today's pre-market session. ↗
Via Chartmill
These stocks that are showing activity before the opening bell on Friday. ↗
Via Chartmill
These stocks that are showing activity before the opening bell on Tuesday. ↗
Via Chartmill
News headline image
Millrose Properties Stock Has Surged 48% Since February Debut — So Why Did One Investor Sell a $23 Million Stake? ↗
A newly public real-estate platform is putting up numbers that look far more seasoned than its age. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Earnings Scheduled For November 10, 2025 ↗
 
Via Benzinga
News headline image
Earnings Scheduled For May 8, 2025 ↗
 
Via Benzinga
News headline image
Earnings Scheduled For February 26, 2025 ↗
 
Via Benzinga
News headline image
Earnings Scheduled For November 12, 2024 ↗
 
Via Benzinga
News headline image
Unveiling 4 Analyst Insights On Theravance Biopharma ↗
 
Via Benzinga
News headline image
Why One Investor Bought $67.5 Million in Array Digital Infrastructure Stock ↗
One fund just made a bold bet on a telecom stock undergoing a big transformation 
Via The Motley Fool
News headline image
Why One Value Fund Has a $101 Million Bet on Indivior Stock Amid a 212% Surge ↗
This fund just doubled down on a stock that’s suddenly delivering the earnings momentum it’s promised for years. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Why One Value Fund Just Bought $30 Million of a Diagnostics Stock Down 90% From Pandemic-Era Highs ↗
A beaten-down diagnostics stock is quietly tightening margins and drawing fresh institutional conviction—here’s what that means for long-term investors. 
Via The Motley Fool
News headline image
Cracking The Code: Understanding Analyst Reviews For Theravance Biopharma ↗
 
Via Benzinga
News headline image
Top movers analysis one hour before the close of the markets on 2025-11-11: top gainers and losers in today's session. ↗
Intrigued by the market activity one hour before the close of the markets on Tuesday? Uncover the key winners and losers of today's session in our insightful analysis. 
Via Chartmill
News headline image
Here's Why Shares in Theravance Biopharma Exploded Today ↗
The company is making excellent progress on all its strategic goals. 
Via The Motley Fool
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
 
Via Benzinga
News headline image
Theravance Biopharma Inc (NASDAQ:TBPH) Reports Q3 2025 Earnings Beat Amid Muted Market Reaction ↗
Theravance Biopharma (TBPH) reported Q3 2025 results, beating EPS estimates with a profit of $0.04. Revenue was slightly below forecasts. Lead drug YUPELRI achieved record sales. 
Via Chartmill
Topics Earnings
News headline image
PACCAR Posts Downbeat Earnings, Joins Neuphoria Therapeutics, Citius Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why Crown Holdings Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Theravance Biopharma Launches Disease Education Campaign to Advance Scientific Understanding of Neurogenic Orthostatic Hypotension Due to Multiple System Atrophy
From Theravance Biopharma
Via Business Wire
News headline image
This Protagonist Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Friday ↗
 
Via Benzinga
News headline image
Theravance Sales Jump 83 Percent ↗
Via The Motley Fool
News headline image
Theravance Biopharma Inc (NASDAQ:TBPH) Misses Q2 2025 Revenue and EPS Estimates Amid Mixed Market Reaction ↗
Theravance Biopharma (TBPH) Q2 2025 earnings missed revenue and EPS estimates, but stock rose 3.1% after-hours. Focus remains on YUPELRI and Ampreloxetine pipeline. 
Via Chartmill
Topics Earnings
News headline image
This Coinbase Global Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday ↗
 
Via Benzinga
News headline image
TBPH Stock Earnings: Theravance Biopharma Beats EPS, Misses Revenue for Q2 2024 ↗
TBPH stock results show that Theravance Biopharma beat analyst estimates for earnings per share but missed on revenue for the second quarter of 2024. 
Via InvestorPlace
News headline image
Earnings Scheduled For August 12, 2025 ↗
 
Via Benzinga
News headline image
Mama's Creations, GameStop And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Sidoti Events, LLC's Virtual June Small-Cap Conference
Via ACCESSWIRE
News headline image
TBPH Stock Earnings: Theravance Biopharma Beats EPS, Beats Revenue for Q1 2024 ↗
TBPH stock results show that Theravance Biopharma beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
News headline image
BTIG Research Predicts Over 118% Rally for These 3 Stocks ↗
Wall Street stock predictions can run wild but after the tech sector's gains, these stocks could be better places for your money. 
Via InvestorPlace
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.